Staar Surgical Co 8-K, filed Sep 24, 2021
Staar Surgical Co (STAA)
About this 8-K
Staar Surgical Co filed this 8-K on September 24, 2021, reporting on events of September 23, 2021.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
|
|
|
|
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code:
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1 933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
|
Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On September 23, 2021, the Board of Directors of STAAR Surgical Company, upon the recommendation of the Compensation Committee and after consideration of data from Radford, an independent compensation consulting firm, approved changes in compensation, effective September 1, 2021, for the following individuals:
|
|
Base Salary |
Bonus Target (as % of Base Salary) |
|
|
|
|
|
Caren Mason |
$799,000 |
105% |
|
|
|
|
|
Patrick Williams |
$500,000 |
75% |
|
|
|
|
|
Scott Barnes |
$495,000 |
45% |
|
|
|
|
|
Keith Holliday |
$478,000 |
50% |
|
|
|
|
|
Hans Blickensdoerfer |
$384,000 |
50% |
The Board of Directors also approved, upon the recommendation of the Compensation Committee, an increase in the maximum target bonus for Company executives from 150% to 200% of target bonus, regarding corporate financial performance for the second half of 2021 pursuant to the pre-established financial metrics regarding fiscal year 2021.
The information furnished herewith pursuant to Item 5.02 of this Current Report, including Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in Item 5.02 of this Current Report shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
STAAR Surgical Company |
||
|
|
||
|
September 24, 2021 |
By: |
/s/ Caren Mason |
|
|
|
Caren Mason |
|
|
|
President and Chief Executive Officer |